Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05137119 · ClinicalTrials.gov registry record · Phase 4
Staphylococcus Aureus Network Adaptive Platform Trial
A Phase 4 study of Staphylococcus Aureus Bacteremia, sponsored by University of Melbourne.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 8,000
- Enrollment target
- 20
- Study locations
NCT05137119 is a Phase 4 study of Staphylococcus Aureus Bacteremia that is actively recruiting participants, run by University of Melbourne. The registered enrollment target is 8,000 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT05137119, a Phase 4 study of Staphylococcus Aureus Bacteremia, is actively recruiting participants, sponsored by University of Melbourne.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 8,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Cefazolin
- DRUG Penicillin
- DRUG Clindamycin
- OTHER Effectiveness of early switch to oral antibiotics
Study Locations (20)
New South Wales
- Blacktown Hospital - Blacktown
- Royal Prince Alfred Hospital - Camperdown
- Concord Repatriation and General Hospital - Concord
- St Vincent's Hospital Sydney - Darlinghurst
- Nepean Hospital - Kingswood
- St George Hospital - Kogarah
- Liverpool Hospital - Liverpool
- John Hunter Hospital - New Lambton Heights
- John Hunter Children's Hospital - Newcastle
- Orange Health Service - Orange
- Prince of Wales Hospital - Randwick
- Sydney Children's Hospital - Randwick
- The Children's Hospital at Westmead - Westmead
- Westmead Hospital - Westmead
- Wollongong Hospital - Wollongong
Queensland
- Sunshine Coast University Hospital - Birtinya
- Cairns Hospital - Cairns
Texas
- Houston Methodist Research Institute - Houston
Australia Capital Territory
- Canberra Hospital - Garran
Northern Territory
- Royal Darwin Hospital - Tiwi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05137119
The ClinicalTrials.gov registry entry for NCT05137119 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Melbourne, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Staphylococcus Aureus Bacteremia appearing as the primary indexed condition, and to 5 interventions - of which Vancomycin is the first listed.
NCT05137119 reports 20 study locations spanning 5 distinct geographic areas - top geographies include New South Wales, Queensland, Texas.
Frequently Asked Questions
What is clinical trial NCT05137119 about?
NCT05137119 is a clinical study titled "Staphylococcus Aureus Network Adaptive Platform Trial". The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
What is the current status of trial NCT05137119?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 8,000 participants. The study started on 2022-02-16. Estimated completion is 2028-12-01.
What conditions does trial NCT05137119 study?
This clinical trial studies the following conditions: Staphylococcus Aureus Bacteremia.
What interventions are being tested in trial NCT05137119?
The interventions under investigation include: Vancomycin (DRUG), Cefazolin (DRUG), Penicillin (DRUG), Clindamycin (DRUG), Effectiveness of early switch to oral antibiotics (OTHER).
Who is sponsoring clinical trial NCT05137119?
This trial is sponsored by University of Melbourne, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05137119 being conducted?
This trial has 20 study locations across Texas, Australia Capital Territory, New South Wales, Northern Territory, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.